首页> 美国卫生研究院文献>Bulletin of the New York Academy of Medicine >Increasing Syringe Access and HIV Prevention in California: Findings from a Survey of Local Health Jurisdiction Key Personnel
【2h】

Increasing Syringe Access and HIV Prevention in California: Findings from a Survey of Local Health Jurisdiction Key Personnel

机译:加利福尼亚州越来越多的注射器使用和艾滋病毒预防:来自当地卫生管辖区关键人员调查的结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This article presents results from the first survey of California local health jurisdictions (LHJs) subsequent to passage of legislation that allows for over-the-counter pharmacy sales of syringes. In 2004 Governor Arnold Schwarzenegger signed Senate Bill 1159 (SB1159) into law to “prevent the spread of HIV, hepatitis and other blood-borne disease among drug users, their sexual partners and their children.” This legislation permits counties and cities to authorize a local disease prevention demonstration project (DPDP). Once authorized, a DPDP permits individuals to legally purchase and possess up to ten syringes from registered pharmacies without a doctor’s prescription. From June to August 2005, we surveyed health departments in all 61 LHJs to assess implementation status of SB1159. Fifty-seven (93%) LHJs responded. Nine (16%) had approved a DPDP by August 2005, 17 (30%) were in the process of obtaining authorization, and 18 (32%) anticipated that SB1159 would never be authorized in their LHJ. Among LHJs that do not plan to approve a DPDP (n = 18), the reasons included: strong community opposition (41%), competing priorities (35%), law enforcement opposition (29%), and little or no interest among pharmacies (29%). In LHJs that have authorized a DPDP, 31.4% of pharmacies registered to legally sell nonprescription syringes. Preliminary results indicate that local coalitions, comprised of public health, waste management and pharmacy officials, have been instrumental in facilitating DPDP authorization. Further research is needed to identify facilitators and barriers to adopting SB1159, to identify areas for improving technical assistance to implementers, and to assess the public health impact of the legislation.
机译:本文介绍了立法通过之后对加利福尼亚州地方卫生管辖区(LHJ)进行的首次调查的结果,该立法允许注射器进行非处方药销售。 2004年,州长阿诺德·施瓦辛格(Arnold Schwarzenegger)签署了第1159号参议院法案,以“防止HIV,肝炎和其他血源性疾病在吸毒者,其性伴侣和子女中传播”。该立法允许县和市批准地方疾病预防示范项目(DPDP)。一旦获得授权,DPDP允许个人在没有医生处方的情况下从注册药房合法购买并拥有多达十个注射器。从2005年6月至2005年8月,我们对所有61家LHJ的卫生部门进行了调查,以评估SB1159的实施状况。 57个(93%)LHJ做出了回应。到2005年8月,已有9家(16%)批准了DPDP,有17家(30%)正在获得授权,还有18家(32%)预计SB1159不会在其LHJ中获得授权。在不打算批准DPDP的LHJ中(n = 18),原因包括:强烈的社区反对(41%),相互竞争的优先事项(35%),执法部门的反对(29%),以及药房之间很少或没有兴趣(29%)。在已批准DPDP的LHJ中,有31.4%的药房注册合法销售非处方注射器。初步结果表明,由公共卫生,废物管理和药房官员组成的地方联盟在促进DPDP授权方面发挥了作用。需要进行进一步的研究,以确定采用SB1159的促进因素和障碍,确定改善对实施者的技术援助的领域,并评估该法规对公共健康的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号